|
Recent News
04/09/13
EyeGate's EGP-437 Matches the Standard-of-Care's Response Rate in Phase III Study of Patients with Anterior Uveitis.
12/18/2012
EyeGate Enrolls Last Patient in Pivotal Phase III Anterior Uveitis Study of EGP-437
10/25/2012
Avedro and EyeGate Pharma Enter Agreement for Corneal Cross-linking IP
Media Inquiries
Stephen From
CEO
Eyegate Pharmaceuticals
781.398.3820
sdfrom@eyegatepharma.com
|
